Published in J Gen Virol on September 01, 1997
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. J Virol (2008) 2.22
Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J Virol (2007) 2.05
Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol (1999) 1.52
Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol (2003) 1.11
Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology (2007) 1.07
Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol (2010) 1.05
Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J (2012) 1.04
The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agent Cancer (2007) 1.03
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
The papillomavirus major capsid protein L1. Virology (2013) 0.98
Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol (2007) 0.96
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health (2009) 0.94
Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. Hum Vaccin Immunother (2013) 0.94
Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol (2006) 0.93
Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol (2003) 0.86
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. BMC Microbiol (2004) 0.85
Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology (2015) 0.85
Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. Virol J (2008) 0.84
Development of a highly thermostable, adjuvanted human papillomavirus vaccine. Eur J Pharm Biopharm (2015) 0.82
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine (2014) 0.81
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. J Virol (2015) 0.78
A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep (2016) 0.76
Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV). PLoS One (2017) 0.75
Evidence for Placental HPV Infection in Both HIV Positive and Negative Women. J Cancer Ther (2015) 0.75
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J (1989) 6.60
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature (1987) 5.61
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
Translation of open reading frame E5 of bovine papillomavirus is required for its transforming activity. Proc Natl Acad Sci U S A (1986) 3.17
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. EMBO J (1987) 2.84
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J (1988) 2.66
Changing clinical spectrum of splenic abscess. A multicenter study and review of the literature. Am J Surg (1987) 2.63
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
The bovine papillomavirus E5 transforming protein can stimulate the transforming activity of EGF and CSF-1 receptors. Cell (1989) 2.52
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol (1997) 2.30
Bovine papilloma virus-transformed cells contain multiple E2 proteins. Proc Natl Acad Sci U S A (1988) 2.29
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol (1998) 2.12
Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology (1996) 2.08
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol (1991) 2.00
Genetic assignment of multiple E2 gene products in bovine papillomavirus-transformed cells. J Virol (1989) 1.97
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother (2000) 1.76
Serologic association between human papillomavirus type 16 infection and esophageal cancer in Shaanxi Province, China. J Natl Cancer Inst (1996) 1.75
The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol (1991) 1.74
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol (1997) 1.66
Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology (1994) 1.64
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol (1997) 1.61
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol (1992) 1.56
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Stimulation of counterregulatory hormonal responses in diabetic man by a fall in glucose concentration. Diabetes (1980) 1.46
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Evaluation and treatment of penetrating cervical injuries. J Trauma (1979) 1.39
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 1.38
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis (1996) 1.36
NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology (2001) 1.34
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol (2001) 1.34
Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol (1995) 1.32
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Papillomavirus is resistant to desiccation. J Infect Dis (1997) 1.30
Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst (1997) 1.29
Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. J Virol (2001) 1.28
Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis (1995) 1.27
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol (1998) 1.23
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer (1995) 1.19
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J Virol (1992) 1.18
A multifaceted study of human papillomavirus and prostate carcinoma. Cancer (1998) 1.18
Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis (1995) 1.17
Ontogenesis of somatomedin and insulin receptors in the human fetus. J Clin Invest (1983) 1.17
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology (1998) 1.15
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
The bovine papillomavirus E5 oncogene can cooperate with ras: identification of p21 amino acids critical for transformation by c-rasH but not v-rasH. Mol Cell Biol (1991) 1.13
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13